Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis

Journal of Crohn's and Colitis

Volumn 8, Issue 7, 2014, Pages 571-581

  Thorlund, Kristian ^a,b   Druyts, Eric ^c   Mills, Edward J ^b,c   Fedorak, Richard N ^d   Marshall, John K ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adalimumab; Anti TNF; Indirect treatment comparison; Infliximab; Meta analysis; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CORTICOSTEROID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT DISEASE; BAYESIAN LEARNING; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; REVIEW; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ADULT; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; COMPARATIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901486729     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.010     Document Type: Review

References (35)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369(9573):1641-1657.
2. Langholz E., Munkholm P., Davidsen M., Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992, 103(5):1444-1451.
3. Masuda H., Iwai S., Tanaka T., Hayakawa S. Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase. J Clin Lab Immunol 1995, 46(3):111-123.
4. Nielsen O.H., Gionchetti P., Ainsworth M., Vainer B., Campieri M., Borregaard N., Kjeldsen L. Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol 1999, 94(10):2923-2928.
5. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999, 34(1):66-74.
6. Sandborn W.J., van Assche G., Reinisch W., Colombel J.F., D'Haens G., Wolf D.C., Kron M., Tighe M.B., Lazar A., Thakkar R.B. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142(2):257-265. [e1-3].
7. Reinisch W., Sandborn W.J., Hommes D.W., D'Haens G., Hanauer S., Schreiber S., Panaccione R., Fedorak R.N., Tighe M.B., Huang B., Kampman W., Lazar A., Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60(6):780-787.
8. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., Colombel J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353(23):2462-2476.
9. Huang X., Lv B., Jin H.F., Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-alpha blockers on ulcerative colitis. Eur J Clin Pharmacol 2011, 67(8):759-766.
10. Rahimi R., Nikfar S., Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-alpha in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007, 13(7):I13-I18.
11. Wilhelm S.M., McKenney K.A., Rivait K.N., Kale-Pradhan P.B. A review of infliximab use in ulcerative colitis. Clin Ther 2008, 30(2):223-230.
12. Mills E.J., Ioannidis J.P., Thorlund K., Schunemann H.J., Puhan M.A., Guyatt G.H. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012, 308(12):1246-1253.
13. Thorlund K., Imberger G., Johnston B.C., Walsh M., Awad T., Thabane L., Gluud C., Devereaux P.J., Wetterslev J. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One 2012, 7(7):e39471.
14. Lunn D., Spiegelhalter D., Thomas A., Best N. The BUGS project: evolution, critique and future directions. Stat Med 2009, 28(25):3049-3067.
15. Järnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlén P., Grännö C., Vilien M., Ström M., Danielsson A., Verbaan H., Hellström P.M., Magnuson A., Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128(7):1805-1811.
16. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23(20):3105-3124.
17. Bucher H.C., Guyatt G.H., Griffith L.E., Walter S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50(6):683-691.
18. Turner R.M., Davey J., Clarke M., Thompson S., Higgins J.P. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol 2012, 41(3):818-827.
19. Dias S., Welton N., Sutton A., Ades A. NICE DSU Technical Support Document 2 - a generalised linear modelling framework fro pairwise and network meta-analysis of randomised controlled trial 2011.
20. Sandborn W.J., Rutgeerts P., Feagan B.G., Reinisch W., Olson A., Johanns J., Lu J., Horgan K., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., de Villiers W.J., Present D., Sands B.E., Colombel J.F. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009, 137(4):1250-1260. [quiz 520].
21. Feagan B.G., Reinisch W., Rutgeerts P., Sandborn W.J., Yan S., Eisenberg D., Bala M., Johanns J., Olson A., Hanauer S.B. The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007, 102(4):794-802.
22. Armuzzi A., De Pascalis B., Lupascu A., Fedeli P., Leo D., Mentella M.C., Vincenti F., Melina D., Gasbarrini G., Pola P., Gasbarrini A. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 2004, 8(5):231-233.
23. Colombel J.F., Rutgeerts P., Reinisch W., Esser D., Wang Y., Lang Y., Marano C.W., Strauss R., Oddens B.J., Feagan B.G., Hanauer S.B., Lichtenstein G.R., Present D., Sands B.E., Sandborn W.J. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141(4):1194-1201.
24. Ferrante M., Vermeire S., Katsanos K.H., Noman M., Van Assche G., Schnitzler F., Arijs I., De Hertogh G., Hoffman I., Geboes J.K., Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13(2):123-128.
25. Gornet J.M., Couve S., Hassani Z., Delchier J.C., Marteau P., Cosnes J., Bouhnik Y., Dupas J.L., Modigliani R., Taillard F., Lemann M. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003, 18(2):175-181.
26. Gustavsson A., Järnerot G., Hertervig E., Friis-Liby I., Blomquist L., Karlén P., Grännö C., Vilien M., Ström M., Verbaan H., Hellström P.M., Magnuson A., Halfvarson J., Tysk C. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010, 32(8):984-989.
27. Ochsenkuhn T., Sackmann M., Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004, 16(11):1167-1171.
28. Oussalah A., Laclotte C., Chevaux J.B., Bensenane M., Babouri A., Serre A.A., Boucekkine T., Roblin X., Bigard M.A., Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008, 28(8):966-972.
29. Probert C.S., Hearing S.D., Schreiber S., Kühbacher T., Ghosh S., Arnott I.D., Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003, 52(7):998-1002.
30. Reinisch W., Sandborn W.J., Bala M., Yan S., Feagan B.G., Rutgeerts P., Radford-Smith G., Xu S., Eisenberg D., Olson A., Colombel J.F. Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis. Inflamm Bowel Dis 2007, 13(9):1135-1140.
31. Sands B.E., Tremaine W.J., Sandborn W.J., Rutgeerts P.J., Hanauer S.B., Mayer L., Targan S.R., Podolsky D.K. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001, 7(2):83-88.
32. Xiong T., Parekh-Bhurke S., Loke Y.K., Abdelhamid A., Sutton A.J., Eastwood A.J., Holland R., Chen Y.F., Walsh T., Glenny A.M., Song F. Overall similarity and consistency assessment scores are not sufficiently accurate for predicting discrepancy between direct and indirect comparison estimates. J Clin Epidemiol 2012, 66(2):184-191.
33. Song F., Xiong T., Parekh-Bhurke S., Loke Y.K., Sutton A.J., Eastwood A.J., Holland R., Chen Y.F., Glenny A.M., Deeks J.J., Altman D.G. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 2011, 343:d4909.
34. Caldwell D.M., Gibb D.M., Ades A.E. Validity of indirect comparisons in meta-analysis. Lancet 2007, 369(9558):270. [author reply 1].
35. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331(7521):897-900.